In short
The value of an annual review is the trend, not the snapshot. Three things are worth more in year two than in year one.
- Direction of travel. A blood pressure of 134 means something different rising from 118 than falling from 152.
- Recalculated risk. Your risk band is recalculated rather than carried over, because it changes with age and with any new diagnosis.
- Fewer false alarms. The first check finds everything accumulated over years. Later ones find only what is new, so a higher share of positives are false.
Treatment Overview
Why is the second review more informative than the first?
Because a single value is a point and two values are a direction. Blood pressure, weight, lipids and glucose all mean more read against last year than against a reference range.
There is also a technical reason. The first round of any screening picks up everything that has accumulated over years, the prevalence screen. Later rounds pick up only what has appeared since. Fewer cases are found, so a larger proportion of positive results are false.
That means a second check finding less than the first is normal, not a sign that the first was wasted.
What actually gets reviewed each year?
| Risk band | Recalculated, not carried over. Age alone moves it, and any new diagnosis moves it more |
| Blood pressure trend | Direction over years, with out of clinic confirmation before any new diagnosis |
| Lipids and glucose | Direction, and whether targets are being met if you are on treatment |
| Weight and waist | Trend. Gaining 2.25 kg or more over years raises metabolic syndrome risk by 21 to 45 per cent |
| Alcohol | Screened every year, as a countable question |
| Screening due | Which age appropriate tests have come due since last time |
What if you are on medication?
Then the review is partly a treatment review: whether the target is being met, whether you are still taking it, and whether it is still the right choice at your current age and risk.
New medication needs earlier follow up than the annual cycle, so those reviews sit outside this schedule rather than waiting for it.
Does an annual check actually reduce mortality?
Not on its own. In a meta analysis of 14 randomised trials covering over 180,000 people, general health checks did not reduce total, cardiovascular or cancer mortality.
They did improve blood pressure, cholesterol and BMI, particularly in higher risk people. That is the honest case for the annual review: it is a mechanism for acting, not a treatment in itself.
Does everyone need one every year?
No. Without chronic conditions, about every three years is reasonable under 50, and yearly from 50. Anyone with a chronic condition needs regular review regardless of age.
There are no strict guidelines on optimal frequency and no evidence base for one, so annual should be a choice rather than a default.
Who Is a Good Candidate?
- You had a baseline assessment last year and want it read as a trend
- You are 50 or over, where yearly review is the usual interval
- You started medication in the last year and want to know whether it is working
- You have a chronic condition that warrants regular review whatever your age
- Something has changed: a new diagnosis, a new medication, or a diagnosis in a close relative
- A new symptom, which needs an appointment now rather than waiting for the annual slot
- Chest discomfort or breathlessness on exertion
- An abnormal result from elsewhere that has not been followed up, which needs dealing with rather than repeating
What Happens During the Consultation
-
1
What has changed since last time
New diagnoses, new medication, new symptoms, and any diagnosis in a first degree relative. A family diagnosis alone can change your screening plan.
-
2
The same measurements, read as a trend
Blood pressure, weight, waist, lipids, glucose and kidney function, compared with last year rather than only with a reference range.
-
3
Risk recalculated
Not carried forward. Age moves the number on its own, and any new risk factor moves it more. Where you were borderline last year, this is often where the decision changes.
-
4
Screening due, and the next interval
Which age appropriate screening has come due, whether anything should now stop, and when you should be seen next.
Program Structure & Follow-Up
What a good annual review changes
- A treatment decision that was borderline last year and is no longer borderline
- A dose or a target, where treatment is not achieving it
- A screening test that has just become appropriate for your age
- A screening test that should now stop
When screening should stop
Breast and colorectal screening continue while life expectancy is at least 10 years. That usually means stopping somewhere between 75 and 85.
It is worth raising years in advance rather than announcing it. The benefit takes time to arrive: for colorectal and breast screening you need to live 10 years for a 1 in 1000 chance of your life being extended, and 16 years for 2 in 1000. Harm from overdiagnosis arrives within weeks.
What happens between reviews
Anything new is dealt with when it happens rather than saved up. That includes a new symptom, a side effect, an abnormal result from elsewhere, or a new diagnosis in the family.
Continuity matters more than comprehensiveness
Patients with an established relationship with one clinician have higher rates of appropriate preventive care. More visits to a regular clinician were associated with more colorectal and breast screening, lower incidence and mortality from both, and lower overall mortality.
That is an argument for seeing the same doctor, not for seeing one more often.
Benefits, Limits & Safety
What the annual review is genuinely good for
Catching drift. Blood pressure, weight and glucose all move slowly enough to be invisible year to year and obvious over five.
It is also where medication decisions get revisited rather than repeated, which is the difference between a prescription being renewed and being reviewed.
What it will not do
- It will not reduce your mortality by itself. That comes from acting on the findings
- It will not find every possible disease, and adding tests to try makes it worse rather than better
- It will not move your calculated risk dramatically, since age is a large part of it
The trap of annual testing
Repeating a test every year that does not need repeating produces borderline results by chance alone, and each one generates further testing. That is why the list of tests is set by the interval that fits each test rather than by the calendar.
Coronary calcium is the clearest example: it is not repeated to see whether treatment is working, because progression adds little to what the first scan said.
Reducing testing is not neglect
Where the recommendation is to do less, the reasoning is given. Patients often experience a reduction in screening as being written off, and it is worth saying explicitly that it is a judgement about benefit and harm rather than about worth.
What the trend shows
Drift in blood pressure, weight and glucose that is invisible year to year, plus whether treatment is actually meeting its target.
Who needs it yearly
Everyone from 50, anyone with a chronic condition, and anyone at borderline cardiovascular risk or above. About every three years otherwise.
Not repeated annually
Coronary calcium scoring, tests whose interval is longer than a year, and anything whose result would not change your plan.
Cost & Program Investment
The review and any tests are quoted before they are booked. The test list is set by the correct interval for each test rather than by the calendar, so a yearly review does not mean a yearly repeat of everything. If your age and health mean a three year interval is more appropriate than an annual one, you will be told that rather than sold a subscription.
Frequently Asked Questions
From 50, yearly is the usual interval, and any chronic condition warrants regular review whatever your age. Below 50 without chronic conditions, about every three years is reasonable. There is no evidence base for an optimal frequency.
No, that is expected. The first round picks up everything accumulated over years. Later rounds find only what is new, so fewer cases and a higher proportion of false positives among the positives.
Not by itself. General health checks did not reduce mortality across 14 randomised trials, though they improved blood pressure, cholesterol and BMI. The benefit comes from acting on what is found.
No. Each test has its own correct interval, and repeating one unnecessarily generates borderline results by chance that then need chasing. Coronary calcium in particular is not repeated to monitor treatment.
Breast and colorectal screening continue while life expectancy is at least 10 years, usually meaning somewhere between 75 and 85. It is worth discussing years in advance rather than announcing it.
It gets dealt with then. A new symptom, a side effect, an abnormal result from elsewhere or a new diagnosis in the family should not wait for the annual slot.
Yes, measurably. Patients with an established relationship with one clinician have higher rates of appropriate screening, lower incidence and mortality from colorectal and breast cancer, and lower overall mortality.
Evidence
Where this information comes from
Every figure on this page is taken from the sources below. All of them are free to read, so you can check them yourself.
- Cardiovascular diseases
- Cardiovascular disease: risk assessment and reduction
- Hypertension in adults: diagnosis and management
This page is general medical information and does not replace a personal consultation. Trial results are averages across large groups, not a prediction for any one person.